| Written by Dr. Yu Hyemi, Co-Director & Board-Certified Plastic Surgeon at Bio Plastic Surgery
If you've searched "Wegovy cancer risk," you've probably come away more confused than when you started. Studies saying it lowers cancer risk sit right next to reports warning it may raise the risk of colorectal or thyroid cancer.
Which is it? And is it safe for me?
This article cuts through the noise and lays out what the research actually says.
Whether you're trying to lose weight but have a family history of cancer, you're already using Wegovy and got spooked by something you read online, or you've personally experienced cancer and still need to manage your weight — this article is for you.
What You Need to Know First: Obesity Itself Is a Cancer Risk Factor
Before we look at what Wegovy does or doesn't do, there's a foundational fact worth establishing: obesity is already a well-documented cancer risk factor.
The World Health Organization (WHO) and major medical associations link obesity to 13–14 types of cancer, including esophageal, colorectal, breast (post-menopausal), endometrial, kidney, and pancreatic cancer.
Fat tissue isn't inert storage. It continuously releases inflammatory compounds, drives insulin resistance, and disrupts hormonal balance. The longer that environment persists, the greater the risk that normal cells take a wrong turn.
That's the question researchers set out to answer: if Wegovy reduces obesity — the underlying condition — could it also reduce the cancer risks that come with it?
Evidence That Wegovy Lowers Cancer Risk
Among the studies published so far, the larger the study population, the more consistently they point in one direction: lower cancer risk.
-
Gastric cancer risk down — 1.1 million patients tracked
In one of the largest studies to date, US researchers followed 1.1 million patients. Those using semaglutide — the active ingredient in Wegovy — showed lower incidence of several cancers, with the most pronounced effect seen in gastric cancer.
-
Skin, breast, and gynecologic cancer risk down — same large-scale study
The same large-scale study also found reduced risk across a wider range of cancer types in semaglutide users, including skin cancer, breast cancer, and female gynecologic cancers — suggesting the protective effect extends well beyond the gastrointestinal tract.
-
Liver cancer risk 58% lower — clinical evidence review
A review pooling findings across multiple studies found that patients using GLP-1 receptor agonists had approximately 58% lower risk of hepatocellular carcinoma, and meaningfully lower colorectal cancer risk compared to certain other treatments.
Researchers point to three mechanisms behind these findings: weight loss directly reduces obesity as a cancer driver; chronic inflammation decreases (one study reported a 53% drop in the inflammatory marker CRP among semaglutide users); and improved insulin resistance quiets signals that can push cells toward abnormal growth.
Evidence That Points the Other Way
Not all research points in the same direction. Here's what the studies on the other side report.
-
Colorectal tumor risk signal — network meta-analysis of 68 RCTs
A network meta-analysis pooling 68 randomized controlled trials reported a signal for increased colorectal tumor risk specifically at the 2.4mg/week dose of semaglutide — which is the dose used in Wegovy for obesity treatment.
-
Kidney cancer observed higher — real-world observational study
A real-world observational study found that while overall obesity-related cancer risk was lower in GLP-1 receptor agonist users, kidney cancer appeared higher, flagging the need for further investigation.
-
FDA warning for a specific thyroid cancer subtype — systematic review & meta-analysis
Animal studies in rats showed thyroid tumor signals with GLP-1 receptor agonists, leading the FDA to issue a warning for medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2). A causal link has not been established in humans, but if you or a family member has a history of either condition, Wegovy is contraindicated.
What You Should Consider Before Starting Wegovy
The reason findings vary is that results differ depending on dose, patient population, and study design. This doesn't mean Wegovy is a contradictory drug — it means not all the answers are in yet.
With that in mind, here are three things worth considering before starting Wegovy.
01. Check your family history.
A personal or family history of medullary thyroid carcinoma or MEN2 is a clear contraindication. Before asking whether Wegovy works, the first question is whether it's appropriate for you at all.
02. Keep in mind that most of the current evidence comes from observational studies.
To establish whether Wegovy has a causal relationship with cancer risk — in either direction — more rigorous prospective clinical trials are needed. The papers themselves acknowledge this. What the current studies show is not that Wegovy prevents cancer, but that people who treated their obesity saw lower cancer rates.
03. Look at your obesity risk before your cancer risk.
Wegovy is a weight management medication. Most of the benefits identified so far are best understood as the result of treating obesity — the underlying condition. Before asking whether Wegovy might affect cancer risk, it's worth asking what cancer risk your current weight may already be creating. That's the more grounded starting point.
-
The conflicting studies reflect both the potential and the limits of what Wegovy can offer. What matters is finding the answer that works for you — and that comes not from searching online, but from a conversation with a physician who has seen your full picture.
Family history, thyroid and kidney status, weight goals, and long-term management after stopping — these are exactly what a consultation is for. If you'd like to find out whether Wegovy is right for you, you can book a visit through the link below.
- Book your visit through TPS — Bio Plastic Surgery, Gangnam
[FAQ]
Q. Can Wegovy be considered a cancer prevention tool?
Not quite — at least not yet. Large studies have observed lower rates of obesity-related cancers among semaglutide users, but this is better understood as a downstream effect of treating obesity than as a direct anti-cancer mechanism. Prospective trials to establish causation are still in progress.
Q. A family member has had colorectal cancer. Should I be worried about Wegovy?
If you have a family history of colorectal cancer, that's something to raise with your physician before starting. The current evidence on semaglutide and colorectal cancer is mixed — studies point in different directions — and the appropriate course depends on your personal and family medical history.
Q. I have a thyroid condition. Can I still use Wegovy?
It depends on the specific diagnosis. Common conditions like hypothyroidism or thyroid nodules are not automatic contraindications. However, Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Make sure you know your exact diagnosis before consulting with your physician.
| Written by Dr. Yu Hyemi, Co-Director & Board-Certified Plastic Surgeon at Bio Plastic Surgery
| Edited by Sia Shin, The Pylon Square
